Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
GSK Pharma: Efficiencies drive growth - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Oct 28, 2003

    GSK Pharma: Efficiencies drive growth

    GlaxoSmithKline Pharma (GSK) has announced its 3QFY04 results. Despite a revival in the domestic pharma market, the company has posted a meager 4% growth in topline (GSK had recorded an impressive 10% growth during 2QFY04 when the domestic pharma industry was going through a tough phase). However, improvement in operating efficiencies has helped the company record a robust 55% growth in bottomline. For 9mFY04, GSK has reported a 4% growth in net sales and a 56% rise in net profit.

    Results at a glance…
    (Rs m) 3QFY03 3QFY04 Change 9mFY03 9mFY04 Change
    Net Sales 2,974 3,104 4.4% 8,364 8,707 4.1%
    Other Income 141.8 152.7 7.7% 307 383 24.7%
    Total expenditure 2,435 2,325 -4.5% 6,856 6,682 -2.5%
    Operating Profit (EBDIT) 539 779 44.6% 1,508 2,025 34.3%
    Operating Profit Margin (%) 18.1% 25.1%   18.0% 23.3%  
    Depreciation 55 43 -21.9% 149 131 -12.1%
    Profit before Tax 626 889 42.1% 1666 2277 36.7%
    Extra-ordinary items (21) 0   (53) 123  
    Tax 232 312 34.6% 604 825 36.6%
    Profit after Tax/(Loss) 374 577 54.5% 1,010 1,575 56.0%
    Net profit margin (%) 12.6% 18.6%   12.1% 18.1%  
    No. of Shares (m) 74.5 74.5   74.5 74.5  
    Earnings per share* 20.1 31.0   18.1 28.2  
    P/E ratio   14.9     16.4  

    GSK managed to marginally outperform the industry growth rate during the periods under review. The company continued to reap rich dividends from its strategy of concentrating on few power brands the demand for which remained strong, resulting in a double-digit growth in the power brands portfolio. However, the cessation of ‘Ranitidine’ exports resulted in a 45% dip in export revenues, which put pressure on the topline.

    However, despite slow topline growth, GSK managed to record strong growth in operating profits. This was primarily on account of higher sales of profitable brands and tight control over expenditure resulting in a 700-basis points improvement in operating profit margins. This coupled with a rise in other income (due to higher interest income), lower depreciation provision and extra-ordinary items have helped the company record a strong growth in bottomline. It is to be noted here that extra-ordinary expense during 9mFY03 relates to VRS and separation charges incurred by the company, while, extra-ordinary income during 9mFY04 relates to profit on sale of its property in Bangalore. The sale of GSK’s Mumbai property is expected to further strengthen the company’s cash flows.

    Recognizing the growth potential in the domestic market with the implementation of product patents post 2005, GSK has decided to gradually launch new products. The company plans to make three new product launches every year. GSK is also planning to enter the high margin chronic areas of CNS and diabetes. The company is also aiming at bringing about a 50% improvement in its sales force efficiency by 2005.

    At Rs 462, GSK is trading at a P/E of 16x its annualised 9mFY04 earnings. Although GSK plans to foray into the lifestyle segment, limited exposure in the same and high DPCO cover remain a cause for concern. However, in view of the impending implementation of product patent, the strategy adopted by the company for preparing itself for the same, its market leadership position and access to parent’s strong product portfolio, we remain positive about the long-term prospects of the company.



    Equitymaster requests your view! Post a comment on "GSK Pharma: Efficiencies drive growth". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 17, 2017 (Close)


    • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks


    Compare Company With Charts